Aiming to become the global leader in chip-scale photonic solutions by deploying Optical Interposer technology to enable the seamless integration of electronics and photonics for a broad range of vertical market applications

Free
Message: Re: Enough of the financing concerns

If you compare the disruptive tech Poet has to a phase 3 pharma drug on the verge of being FDA approved, Mazan's share price evaluation is quite plausible.

--------

Only would make sense if such sale would exclude all the patents that do not relate to the OI. An acquirer should not get those as if they were toss-offs at an estate sale.

Share
New Message
Please login to post a reply